Evolus Announces Participation in September Investment Conferences
Evolus, Inc. (NASDAQ: EOLS) announces participation in two investment conferences this September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) announces participation in two investment conferences this September. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, available on-demand from 7:00am ET. The second is the Cantor 2021 Virtual Global Healthcare Conference on September 28 at 3:20pm ET. Both webcasts will be accessible on Evolus' investor relations website for 90 days post-presentation. Evolus is known for its innovative beauty products, including Jeuveau®, the first neurotoxin dedicated to aesthetics, approved by the FDA in 2019.
Positive
- Participation in two significant investment conferences could enhance investor engagement and awareness.
- Evolus' unique product Jeuveau® positions it advantageously in the growing aesthetics market.
Negative
- None.
Details
News Market Reaction – EOLS
The recorded move for EOLS in the trading session of this news was +1.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWPORT BEACH, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in two investment conferences in September.
| Event: | H.C. Wainwright 23rd Annual Global Investment Conference |
| Date: | Monday, September 13, 2021 |
| Time: | Available on-demand starting at 7:00am ET |
| Event: | Cantor 2021 Virtual Global Healthcare Conference |
| Date: | Tuesday, September 28, 2021 |
| Time: | 3:20pm ET |
Audio webcasts of these events will be available on the investor relations section of Evolus’ website at www.evolus.com. Replays of the webcasts will be available for 90 days after the date of each presentation.
About Evolus, Inc.
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Evolus, Inc. Contacts:
Investor Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com
Media Contact:
Crystal Muilenburg, Evolus, Inc.
Chief Marketing Officer
Tel: 949-284-4506
Email: media@evolus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.